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Background: In cystic fibrosis (CF), chronic endobronchial infection with Pseudomonas aeruginosa is a serious complication. Macrolides
can increase lung function and weight in patients, and reduce exacerbations.
Methods: In 2001, we introduced long-term, low-dose azithromycin (AZ) treatment as an integral part of our routine treatment of these
patients. Our study is an observational cohort study of all CF patients with chronic P. aeruginosa infection in our CF center comparing
clinical parameters of the patients 12 months prior to treatment with the same values during 12 months of treatment.
Results: 45 patients (27 men, median age 29 years) completed 1-year treatment. Median weight increased from 63.1 kg in the pre-treatment
period to 63.9 kg during treatment ( p=0.01). Median slope of decline in lung function increased from pre-treatment FEV1 4.1% and FVC
3.0% to +0.8% ( pb0.001) and +1.6% ( p=0.01), respectively. 90% of sputum samples contained mucoid P. aeruginosa before treatment,
decreasing to 81% during treatment ( p=0.003). Median CRP decreased from 6.2 mmol/l to 5.8 mmol/l (ns).
Conclusion: Long-term, low-dose AZ treatment in adult CF patients with chronic P. aeruginosa infection is safe and reduces the decline in
lung function, increases weight, and reduces the percentage of mucoid strains of P. aeruginosa in sputum samples.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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In cystic fibrosis (CF), the most frequent serious clinical
complication today is chronic endobronchial infection with
Pseudomonas aeruginosa, a microorganism characterized
by the ability to produce large amounts of alginate, and to
grow as a biofilm where microcolonies of bacteria
embedded in a matrix of alginate invade the lower
respiratory tract. The biofilm mode of growth is a survival
strategy, which protects the bacteria from host immune1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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F Deceased.reactions and antibiotics, and it is therefore the most
important virulence factor [1]. The chronic nature of this
infection leads to a vigorous and sustained inflammatory
response and subsequent tissue damage [2] and, in the past,
95% of patients with CF have succumbed to respiratory
failure due to this pathogen.
Diffuse pan-bronchiolitis (DPB) is a rare lung disease of
unknown etiology seen in adult Japanese patients, in which
chronic endobronchial infection with P. aeruginosa leading
to respiratory failure is common. Surprisingly, it was found
that long-term treatment with macrolide antibiotics resulted
in markedly increased long-term survival of patients with
DPB. A preliminary study of seven children with CF and P.
aeruginosa infection revealed a marked increase in lung
function during long-term azitromycin (AZ) treatment [3],
and two subsequent intermediate-term controlled trials
showed improvement in several clinical and paraclinicals 4 (2005) 35–40ed by Elsevier B.V. All rights reserved.
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majority of whom had P. aeruginosa infection [4], and one
in children, half of whom appeared to be chronically
infected with P. aeruginosa [5]. A recent retrospective
study showed an increase in lung function and BMI in a
selected group of patients with chronic P. aeruginosa
infection and rapid progression of the lung disease in those
who were treated with macrolides as compared to a group of
patients with P. aeruginosa infection and stable lung
function [6].
Following the very encouraging results in the first two
reports [3,4], we decided to incorporate long-term low-dose
AZ treatment in our routine protocol for treatment of all
patients with CF and chronic P. aeruginosa infection. In the
present study, we assessed the safety of long-term treatment
and the effect of this intervention on lung function,
nutrition, and bacteriology.2. Patients and methods
The diagnosis of CF was established on the basis of
abnormal sweat electrolytes, characteristic clinical features,
and genotype.
All CF patients are seen on a regular monthly basis. At
each visit, the clinical status of the patients is assessed by
weight and lung function parameters (forced vital capacity
(FVC) and forced expiratory volume in 1 s (FEV1);
Pneumothac, Draeger). Lower respiratory tract secretions
are obtained by coughing (sputum producers) or naso-
laryngeal suction, and sputum microbiology, including
isolation and characterization of mucoid and non-mucoid
P. aeruginosa phenotypes, is carried out. Infection is
considered chronic when P. aeruginosa has been cultured
from secretions for six consecutive months or less if there
simultaneously is an increase in precipitating antibodies
against P. aeruginosa [7].
All patients are treated according to fixed guidelines,
which include aggressive anti-P. aeruginosa antibiotic
treatment, PEP mask, and daily administration of Pulmo-
zyme. No patients receive prophylactic anti-staphylococcal
antibiotics [8]. This treatment was not changed during the
observation period. Neither was there any change in
nutritional support.
The study is an observational cohort study including all
of our adult CF patients with chronic P. aeruginosa
infection.
Fifty-three adult patients (32 males) started AZ treatment.
45 (27 males) completed 1 year of treatment with low-dose
AZ, 250 mg daily. Two patients stopped the treatment
because of adverse effects (tinnitus, which was reversible
when the treatment stopped) and one because of planning of
a pregnancy. Five patients could not be evaluated because of
insufficient clinical follow-up. Median age was 29 years
(range 17.5–50). Median duration of chronic P. aeruginosa
infection was 22 years (range 2–31); all patients arechronically infected with both mucoid and non-mucoid
phenotypes.
On average, the patients were examined 8.6 times in the
pre-treatment period, and 8.0 times in the treatment period.3. Statistical analysis
The means of the values for each period of time (pre-
treatment and during treatment) were calculated and
compared using a simple t test, paired two-sample for
means. If more than one lung function test was performed,
or if more than one sputum sample was investigated per
month, the mean of the results was calculated and used for
statistic analysis.
The slope of decline of lung function during 1 year was
calculated, using linear regression, then compared in the
same manner as mentioned above. Level of significance was
b0.05 (two-tailed).4. Results
4.1. Weight
The weight increased from a median of 63.1 kg (range
46.9–108.4) in the pre-treatment period to a median of 63.9
kg (46.8–114.3) in the treatment period ( p=0.01).
Body mass index (BMI) increased from a median of 21.9
(17.6–34.1) to a median of 22.0 (17.7–36.1) ( p=0.03).
4.2. Lung function
Using linear regression, we calculated the slope of
decline, expressed as percent of predicted value, during 1
year. During the pre-treatment period, the median slope of
decline was 4.1% for FEV1 (21.5% to 12.3%) and
3.0% for FVC (39.5% to 13.6%).
During the year of treatment, the slope of decline
changed significantly. The median slope of decline for
FEV1 changed to a positive value of +0.8% (10.5% to
31.3%, pb0.001) for FVC +1.6% (14.4% to 22.5%,
p=0.01). The changes in slope of FEV1 in individual
patients in the pretreatment and treatment periods are
illustrated in Fig. 1.
31 of 45 patients (69%) responded well to the treatment,
reducing the rate of decline in FEV1. The remaining 14
patients had an increased rate of decline in FEV1.
4.3. Prevalence of mucoid P. aeruginosa in sputum
In the pre-treatment period, we found that a median of
90% (range 0–100) of lower respiratory tract (LRT) samples
contained mucoid strains. In the treatment period, this










































Fig. 1. The slope of decline in lung function in the year before and during treatment. The mean slope of decline of all patients (thick, black line) and the
individual values (gray lines).
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The sputum samples are examined for growth of all
common CF relevant microorganisms, and changes in the
bacterial flora in the sputum samples during AZ treatment
were evaluated. None of the patients was infected with
Burkholderia species and the percentage of sputum samples
containing Achromobacter xylosoxidans, Moraxella cathar-
ralis, Streptococcus pneumoniae, and Haemophilus influ-
enzae did not change during the treatment period. The
percentage of cultures containing Stenotrophomonas malto-
philia increased slightly from a mean value of 3.3% to 5.0%
(ns). The percentage of cultures containing Staphylococcus
aureus decreased significantly, from a mean value of 11.4%
to 7.6% ( p=0.02).
4.5. C-reactive protein (CRP)
Blood samples were collected at each intravenous
course of antibiotics, and at least once a year. In the year
prior to treatment, the median CRP value was 6.2 mmol/l
(range 3–44.5). In the treatment period, the median CRP
was 5.8 mmol/l ( p=0.13). One patient had an episode of
kidney stone during the treatment period, resulting in
urinary tract infection and an outstanding CRP of 132
mmol/l. Omitting that value from the analysis resulted in
the drop in CRP becoming statistically significant
( p=0.02).
The number of days on intravenous antibiotics did not
change, being 51.5 days before treatment and 52.0 days
during treatment.4.6. Safety
With the exception of two patients with tinnitus, the
patients reported no adverse effects.5. Discussion
Several clinically controlled, randomized intervention
studies have been published, which shows significant effects
of AZ on lung function and other clinical parameters of CF
patients with chronic P. aeruginosa infection [4,5,9]. It is,
however, well-known that the selection criteria for con-
trolled, randomized studies may result in trials that do not
properly reflect all CF patients suffering from this infection.
Observational cohort studies like the present compensate for
this problem [10].
This open observational cohort study of 12-month low-
dose AZ treatment, in an unselected group of 45 adult
patients with CF and chronic P. aeruginosa infection,
showed that a negative annual slope of decline of FEV1
was changed from 4.1% of the predicted value to a
positive annual slope with an increase of +0.8% correspond-
ing to a difference of +4.9%. Wolter et al. [4] studied the
effect of 250 mg of AZ daily for 3 months in a parallel
placebo-controlled study of 30 adult patients and found a
decline in FEV1 of 3.6% in controls as opposed to no
change in the treated group. Only 83.3% of the patients
carried mucoid P. aeruginosa. Equi et al. [5] studied the
effect of AZ treatment in 41 children with CF (aged 8–18
years) in a 26 months cross-over placebo controlled study
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+5.4% between AZ and placebo. It is unclear how many
of the patients had chronic P. aeruginosa infection but
nearly all (38/41) were on inhaled anti-pseudomonal
antibiotics. Similar results are reported by Saiman et al.
[9] with +6.2% in mean difference in FEV1 between AZ
and placebo group. Baumann et al. [11] found an increase
in lung function of 12.8% in patients treated with AZ,
250 mg/day.
All studies thus showed a significant increase in FEV1%
in the AZ-treated patients, which is likely to be due to
decreased inflammation in the bronchial lumen. We found a
decrease in CRP, which was statistically significant after
exclusion of one patient with a CF non-related urinary tract
infection. Wolter et al. [4] found a significant reduction in
CRP but not ESR in the treated patients, while Equi et al. [5]
did not include ESR or CRP in their study. Saiman et al. [9]
found no difference in the levels of elastase and IL-8
between the two groups.
Lung infection and inflammation in patients with CF are
often reflected in loss of weight and we detected a slight but
statistically significant increase of 0.8 kg ( p=0.01) and BMI
( p=0.03) in the treated patients. A similar positive effect on
weight in the treatment group was reported by Saiman et al.
[9]. The weight of the patients was not recorded in the study
by Equi et al. [5], and Wolter et al. [4] found no statistical
significant difference in BMI between placebo and AZ-
treated patients, but BMI is a less sensitive marker than
weight, the number of patients was smaller, and the
treatment period was shorter than in our study and the
study by Saiman et al. [9].
Improved lung function and evidence of decreased
inflammation in AZ-treated patients could presumably be
due to anti-infectious and/or anti-inflammatory effects of
AZ. Sputum cultures are obtained on a regular basis and we
found a significant decrease in the percentage of cultures
positive for S. aureus, which may have contributed to
decreased lower airway infection and inflammation.
Although the decrease was statistically significant ( p=
0.02), it was numerically small (from 11.4% to 7.6% of
sputum samples) and cannot explain the observed increase
in lung function since all patients are cultured once every
month and because a positive culture of S. aureus from LRT
secretions will be treated aggressively irrespective of the
clinical condition. In the study by Equi et al. [5], there were
no changes in frequency of isolation or colony density of S.
aureus during the study period as compared to the previous
period. In the study by Wolter et al. [4], there were no
differences in organisms isolated or bacterial counts
between the placebo and AZ-treated groups at baseline or
at final assessment and thus no evidence that clinical
improvement was due to treatment of bacteria susceptible
to macrolides. In the study by Saiman et al. [9], no
difference in eradication rate of S. aureus were found
between the groups. On the other hand, there were less
patient in the AZ group with newly acquired S. aureusinfection at the end of the study, when compared to the
placebo group.
Some CF centres prescribe prophylactic anti-staphylo-
coccal antibiotics. We do not recommend that azithromycin
be used in this way because of the risk of encouraging
bacterial resistance [12].
The interesting microbiological finding in the present
study was the small but highly significant ( p=0.003)
reduction in the number of sputum samples positive for
mucoid strains from 90% in the year before treatment to
81% in the year of AZ treatment. Patients were selected if
chronically infected with P. aeruginosa and the large
majority had, for many years prior to study, harbored both
mucoid and non-mucoid strains. This indicates that AZ may
have had a selective activity against mucoid (i.e., alginate-
producing strains, or mucoid strains rendered non-mucoid in
accordance with its known inhibitory activity on a key
enzyme in alginate biosynthesis) [13]. In the study by
Wolter et al. [4], 57 of 60 patients had sputum analysis at
entry, where 83.3% carried mucoid strains and 66.6% non-
mucoid. The authors found no significant difference in
quality or quantity of pathogens at baseline, or at final
assessment between the AZ and placebo groups. Since that
study included 30 AZ-treated patients followed over 3
months, as compared to the present 45 patients followed
over 12 months, it is possible that the number of sputum
samples was too small to disclose a change in phenotype in
the treated group. In the study of Equi et al. [5], chronic
infection with P. aeruginosa was not an entry criterion and
only half of the patients (21/41) had three positive cultures
in the year prior to entry. The authors found no difference in
the number of isolates of P. aeruginosa or in the colony
density between treatment and placebo periods, but it
appears that many patients received nebulized anti-pseudo-
monal prophylaxis (38/41) during the trial. Furthermore, the
authors apparently did not distinguish between morphotypes
of cultured P. aeruginosa. In the study by Saiman et al. [9],
only two sputum or throat cultures were done during the
study, one at inclusion and one at day 168. There was no
difference between the two groups with regard to occurrence
of mucoid phenotype.
Probably because of the rigorous aggressive antimicro-
bial treatment of the present patients, including elective
intravenous antibiotic courses every 3–4 months, we could
not detect changes in exacerbations of lung disease or in
demand for antibiotics. Wolter et al. [4] found a significant
reduction in respiratory exacerbations and demand for
hospitalization and intravenous antibiotic treatment, as well
as improved quality of life scores. In the study by Equi et al.
[5], the treated group received fewer additional courses of
oral antibiotics than the placebo group but they did not
detect differences in the number of pulmonary exacerbations
and intravenous courses of antibiotics. The patients in the
latter study were younger and the study probably had less
patients with chronic P. aeruginosa infection than the study
by Wolter et al. [4]. In the study by Saiman et al. [9], there
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groups concerning days in hospital and days on intravenous
treatment.
The overall conclusion from the present and other studies
is that long-term AZ treatment of patients with CF and
chronic broncho-pulmonary P. aeruginosa infection leads to
reduced inflammation resulting in substantial improvement
in lung function and decreased morbidity. It is yet unclear
whether this effect comes from sub-MIC inhibition of the
microorganisms, or from modulation of the local inflam-
matory response to the infection.
Chronic P. aeruginosa lung infection in patients with CF
and in patients with DPB is a biofilm where the bacteria
form complex community structures [14]. To do so, the
bacteria depend upon a system of cell-to-cell communica-
tion, which is termed bquorum sensing.Q P. aeruginosa
synthesize and release small self-generated signal molecules
acting as bautoinducersQ since each individual cell can
synthesize as well as respond to the signal molecule
(synthesis and detection of extracellular signals) [15–17].
P. aeruginosa strains defective in genes controlling quorum
sensing signaling have markedly reduced virulence in an
animal model, and a large number of genes are regulated by
quorum sensing signals, many of which code for putative
virulence factors, among which are genes coding for
alginate production.
The important observation that long-term macrolide
therapy significantly increased survival of patients with
DPB and chronic P. aeruginosa infection [13] has led to a
number of in vitro and in vivo studies. It has been shown
that macrolides including AZ at concentrations far below
minimal inhibitory concentrations (MIC) suppress protein
synthesis and synthesis of virulence factors including
alginate production in P. aeruginosa, which may lead to
loss of viability with prolonged exposure [18–24], and AZ
specifically inhibits quorum sensing [25]. There is evidence
suggesting that AZ at a concentration of as little as 2 Ag/ml
(which is 1/64 of MIC) may be bactericidal to P. aeruginosa
in stationary growth phase but not in exponential growth
phase [20,26].
Another possible way of action in damaging the bacteria
has been mentioned by Saiman et al. [27]. AZ has been
shown to, in vitro, act synergistically against P. aeruginosa
and other bacteria when combined with other antibiotics. All
our patients receive regular courses of intravenous anti-
biotics during AZ treatment.
There is, however, increasing evidence that macrolide
antibiotics may possess anti-inflammatory properties
through interference with different parts of the immune
system [28–31]. Of particular interest to CF and DPB is the
finding that the number of neutrophils and the amount of
neutrophil-derived elastolytic-like activity are reduced in
bronchoalveolar lavage (BAL) fluid after treatment of DPB
patients with erythromycin [32] and that AZ modulates
PMN function and inflammatory markers in healthy human
volunteers [33]. Two other macrolides, flurythromycin anderythromycin, have been shown to inhibit human neutrophil
elastase in vitro [34].
Our work is the first to show a significant fall in the
amount of mucoid strains when AZ is used in vivo against P.
aeruginosa, consistent with the results of several in vitro
studies. The exact mechanism remains to be found.6. Conclusion
Long-term, low-dose AZ treatment in adult CF patients
with chronic P. aeruginosa infection has the ability to
inhibit the formation of biofilm by the bacteria, shown by a
decrease in sputum samples containing mucoid P. aerugi-
nosa. We confirmed that long-term AZ treatment is safe and
had a significant positive effect on the course of CF lung
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